Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Which Is Right for You?

What These Two Drugs Actually Do to Bone

These are fundamentally different drugs, not two versions of the same thing. Understanding the mechanism matters because it drives sequencing decisions.

Reclast (zoledronic acid) works by binding to hydroxyapatite at bone resorption sites and triggering osteoclast apoptosis. The result is slower bone breakdown. It does not directly stimulate new bone formation. One 5 mg IV infusion per year is enough because the drug embeds in bone mineral and releases slowly over months [1].

Evenity (romosozumab) targets sclerostin, a protein made by osteocytes that normally puts a brake on bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation AND decreases bone resorption. This dual action is rare in osteoporosis pharmacology. The trade-off is that the anabolic window closes after 12 months, so Evenity is always a timed course, not an open-ended treatment [2].

Why the Mechanism Gap Matters for Women

For a woman in her mid-50s who has just lost several years of estrogen protection and is entering early postmenopause with a T-score of -3.0 at the spine, bone turnover is brisk and remodeling is in overdrive. An agent that can simultaneously lay down new bone and slow resorption offers a structural advantage over one that only slows breakdown.

For a woman in her late 70s with a prior fragility fracture and no recent cardiovascular event, a once-yearly IV infusion that she does not have to remember weekly may be far more practical.

The mechanism also dictates what happens after you stop. Gains from Evenity erode quickly without follow-on therapy. Reclast's binding to bone mineral provides residual effect for two to three years in most women, which is why drug holidays are more feasible with bisphosphonates [1].

The Trial Evidence: What Was Actually Studied in Women

Both key trials enrolled primarily postmenopausal women, which is a meaningful point in an era when women are routinely underrepresented in clinical research.

HORIZON-PFT: The Foundation for Zoledronic Acid

The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Key Fracture Trial enrolled 7,765 postmenopausal women aged 65 to 89 with either a femoral neck T-score of -2.5 or lower, or a T-score of -1.5 with preexisting vertebral fractures. At three years, zoledronic acid reduced vertebral fracture risk by 70% and hip fracture risk by 41% compared with placebo [1].

Bone mineral density at the lumbar spine increased 6.7% at three years. At the total hip, the gain was 6.0% [1]. These are meaningful numbers for antiresorptive therapy.

A follow-up extension demonstrated that women who received six years of zoledronic acid maintained benefit, but those who stopped after three years retained protection for an additional three years without further treatment, supporting the concept of a drug holiday in lower-risk patients [1].

ARCH: The Key Trial for Romosozumab

The Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk enrolled 4,093 postmenopausal women aged 55 to 90, all with a prior vertebral fracture and low bone density. Participants received either romosozumab 210 mg monthly or weekly alendronate for 12 months, then all switched to alendronate. By 24 months, the romosozumab-then-alendronate group had a 48% lower rate of new vertebral fractures compared with the alendronate-alone group [2].

The cardiovascular signal appeared here too. Serious cardiovascular events occurred in 2.5% of the romosozumab group vs 1.9% in the alendronate group in the first 12 months, leading to the FDA boxed warning [2].

The Evidence Gap You Deserve to Know

Neither trial included premenopausal women except in rare protocol exceptions. Neither specifically studied women with PCOS-related bone deficits, breast-cancer-treatment-induced bone loss, or postpartum osteoporosis. Data in these groups is largely extrapolated from postmenopausal populations or small observational studies. When your clinician recommends either drug off the primary-indication profile, ask them to name the evidence base.

Head-to-Head in Special Populations

No randomized controlled trial has put zoledronic acid directly against romosozumab in the same group of women. The ARCH trial compared romosozumab to alendronate, not to zoledronic acid. Head-to-head decisions are made by applying trial data to individual patient characteristics.

Women With a Prior Vertebral Fracture

This is the clearest win for starting with Evenity. The ARCH trial was built on this population. A woman with one or more prior vertebral fractures is classified as very high fracture risk under the American Association of Clinical Endocrinology 2020 guidelines, and those guidelines suggest anabolic-first sequencing in very high risk [3]. Romosozumab for 12 months, then transitioning to Reclast or another antiresorptive, has the strongest evidence base for this group.

Women With a Prior Hip Fracture

Reclast has a specific, powerful signal here. HORIZON-PFT included a separate 2,127-patient trial of women and men who had recently suffered a hip fracture. Zoledronic acid reduced new clinical fractures by 35% and overall mortality by 28% in that group [1]. Romosozumab's evidence in post-hip-fracture patients is thinner.

Women With Chronic Kidney Disease

This is a critical distinction. Zoledronic acid is contraindicated when creatinine clearance is below 35 mL/min [1]. Women with stage 3b or worse CKD should not receive Reclast. Romosozumab has been used cautiously in mild-to-moderate CKD, but data are sparse and manufacturer guidance recommends caution below GFR 30 mL/min [2]. Neither drug has strong trial data in women on dialysis.

Women who develop autoimmune conditions such as lupus nephritis, which disproportionately affects women, may develop CKD that makes Reclast a poor long-term choice. This is a population where the treatment algorithm deserves individualized re-evaluation.

Women With a Recent Cardiovascular Event

Do not use Evenity. Full stop. The FDA boxed warning specifically flags myocardial infarction and stroke risk [2]. Any woman who has had an MI, stroke, or TIA within the past year should not receive romosozumab. Reclast is not contraindicated in these women and is the default choice.

Women on Aromatase Inhibitors for Breast Cancer

Aromatase inhibitor (AI) therapy drives significant bone loss, often 2 to 4% per year at the spine during the first two years of treatment. Zoledronic acid has the most trial data in this setting: the Z-FAST and ZO-FAST trials demonstrated that upfront zoledronic acid preserves bone density in premenopausal women rendered postmenopausal by AI therapy [1]. Romosozumab has not been studied prospectively in AI-associated bone loss, so Reclast has a clearer evidence base here.

Women With PCOS

PCOS is associated with complex metabolic and hormonal changes that affect bone in ways that are not fully understood. Elevated androgens may offer some bone protection, but insulin resistance, low progesterone, and chronic low-grade inflammation can counteract this. Most PCOS-related fracture risk management is extrapolated from general osteoporosis guidelines because neither Reclast nor Evenity has been studied specifically in PCOS populations. If a woman with PCOS has a formal osteoporosis diagnosis and meets treatment criteria, the same special-population considerations above apply.

Women With Glucocorticoid-Induced Osteoporosis

Zoledronic acid has a dedicated FDA indication for glucocorticoid-induced osteoporosis [1]. Women with inflammatory conditions such as rheumatoid arthritis or inflammatory bowel disease who require long-term steroids have a specific evidence base for zoledronic acid. Romosozumab's role here is emerging but not yet guideline-endorsed for this specific indication.

Sex-Specific Pharmacology: How Your Hormonal Status Changes the Picture

Estrogen and bone metabolism are deeply connected, and your hormonal status at the time of treatment changes how these drugs behave.

Early Postmenopause (Within 5 Years of Final Menstrual Period)

Bone loss is fastest in the first two to three years after the final menstrual period, driven by the abrupt drop in estrogen. The Menopause Society (NAMS) 2023 position statement notes that hormone therapy remains an option for fracture prevention in younger postmenopausal women at elevated risk, and that antiresorptive or anabolic therapy should be layered on when T-scores meet treatment thresholds [4]. If you have entered menopause early, whether surgically or naturally, and your T-score is already at -2.5 or below, bone turnover is likely brisk enough that Evenity's dual mechanism may confer a larger absolute benefit over the 12-month course.

Late Postmenopause (More Than 10 Years Past Final Menstrual Period)

Bone remodeling rate slows somewhat with advancing age, and fracture risk at the hip becomes proportionally more important. Reclast's 41% hip fracture reduction from HORIZON-PFT is a strong argument here. Tolerability also matters: an older woman managing multiple medications may find a once-yearly infusion far simpler than two monthly injections.

Premenopausal Women and Younger Patients

Neither drug is approved for premenopausal use outside of specific secondary osteoporosis settings (glucocorticoid-induced being the main one for zoledronic acid). Bone mass accrues until approximately age 25 to 30, and treatment decisions in premenopausal women require specialist input.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Both drugs are contraindicated in pregnancy. This section is not a formality. It is clinically essential, particularly for any woman in her 40s who may not yet be certain she is postmenopausal.

Zoledronic Acid (Reclast) in Pregnancy and Lactation

Zoledronic acid is classified as FDA Pregnancy Category D (the older categorization) and carries serious reproductive risk. Bisphosphonates incorporate into the maternal skeleton and can be released slowly over years, including during a subsequent pregnancy. Animal data show skeletal and fetal abnormalities with bisphosphonate exposure [1]. Human data are limited to case reports and registries, but the concern is real: fetal hypocalcemia and skeletal deformity have been reported.

Lactation transfer of zoledronic acid is poorly studied in humans. Given the drug's skeletal binding and slow release, the theoretical risk of transfer via breast milk exists. The FDA label advises against use during breastfeeding [1].

For any woman of reproductive potential receiving zoledronic acid, reliable contraception is recommended. The long skeletal half-life means the drug persists well beyond the infusion.

Romosozumab (Evenity) in Pregnancy and Lactation

Romosozumab is contraindicated in pregnancy. Animal studies show fetal skeletal abnormalities with sclerostin inhibition, consistent with sclerostin's essential role in fetal bone development [2]. The FDA label for Evenity requires that women of reproductive potential use effective contraception during treatment and for a defined period after the last dose [2].

Lactation data are absent. Until human lactation data exist, breastfeeding during romosozumab therapy is not advised.

Practical Guidance by Life Stage

For a woman in perimenopause who is not yet certain she has completed her final menstrual period: confirm cessation before initiating either drug, or use highly effective contraception throughout the treatment course. A 12-lead ECG and cardiovascular risk assessment should precede any Evenity prescription. Reclast requires a baseline serum creatinine and should not be administered if GFR is below 35 mL/min.

Should You Switch From Reclast to Evenity?

Switching direction matters enormously in osteoporosis sequencing. The general principle in guidelines is anabolic therapy first, then antiresorptive, because antiresorptive agents given first blunt the response to subsequent anabolic therapy.

Switching From Reclast to Evenity: What the Evidence Shows

If you have been on Reclast for three or more years and have had a new fracture or your T-score has continued to decline despite therapy, escalation to Evenity may be appropriate. The ARCH trial enrolled women who had been previously treated with antiresorptives, and the romosozumab group still outperformed continued alendronate [2]. This suggests a meaningful gain is achievable even after bisphosphonate exposure.

However, the anabolic response may be attenuated. Prior bisphosphonate use suppresses bone turnover markers, and the anabolic effect of romosozumab is partly dependent on baseline bone formation capacity. Women who have been on Reclast for five or more years may see a smaller spike in bone formation markers during Evenity therapy compared with bisphosphonate-naive women. This does not mean the switch is futile, but you and your prescriber should set realistic expectations.

Switching From Evenity to Reclast: The Standard Sequence

This is the approved and guideline-recommended sequence. Evenity for 12 months, then transition to Reclast or another antiresorptive to consolidate gains. Without follow-on antiresorptive therapy, bone density gains from Evenity are substantially lost within 12 months of stopping [2]. The Menopause Society guidelines align with using sequential antiresorptive therapy after anabolic agents [4].

A practical decision framework for sequential therapy by fracture risk:

| Risk Level | Recommended Start | Follow-On | |---|---|---| | High (T-score -2.5 to -3.0, no fracture) | Reclast or oral bisphosphonate | Drug holiday at 3-5 years if stable | | Very high (T-score <-3.0 or prior fracture) | Evenity 12 months | Reclast for 3 years | | Prior hip fracture | Reclast (strong hip data) | Continue or reassess at 3 years | | Recent CV event | Reclast only (Evenity contraindicated) | Continue Reclast, reassess annually | | CKD (GFR <35) | Neither; consult nephrology | Denosumab often used instead |

Side Effects and Tolerability: A Women-Centered Look

Reclast Side Effects

The most common side effect is an acute phase reaction in the first 24 to 72 hours after infusion: flu-like symptoms, fever, bone pain, and myalgia occurring in approximately 30 to 40% of women after the first dose, much less frequently with subsequent doses [1]. Pre-medicating with acetaminophen and hydrating well before the infusion reduces severity.

Rare but serious risks include osteonecrosis of the jaw (ONJ) and atypical femoral fractures, both shared with other bisphosphonates. The absolute risk of ONJ from once-yearly Reclast for osteoporosis is very low, estimated at fewer than 1 in 10,000 treatment-years for women receiving low-dose bisphosphonate therapy for osteoporosis (as opposed to the much higher doses used in cancer treatment).

Evenity Side Effects

Injection site reactions are common. The cardiovascular risk is the most serious concern, warranting the boxed warning [2]. Arthralgia and headache are among the more common non-cardiac complaints. ONJ and atypical femoral fractures are listed as rare risks for Evenity as well, though the 12-month course limits cumulative skeletal exposure.

Who This Treatment Is and Is Not Right For

Evenity (Romosozumab) Is Likely Right For You If:

• You are postmenopausal, have a T-score of -2.5 or lower, and have had at least one vertebral fracture
• You have never had a heart attack, stroke, or TIA
• You have adequate kidney function
• You are within five to ten years of menopause and bone remodeling is active
• You can receive two monthly subcutaneous injections in a clinical setting for 12 months

Evenity Is Not Right For You If:

• You have had a heart attack or stroke in the past year
• You are pregnant, breastfeeding, or not using reliable contraception and still have ovarian function
• You have severe renal impairment
• You need a very long-term, maintenance approach and prefer the simplicity of one annual infusion

Reclast (Zoledronic Acid) Is Likely Right For You If:

• You have had a hip fracture and need demonstrated hip-fracture-reduction data
• You are taking aromatase inhibitors and need evidence-based bone protection
• You have cardiovascular risk factors that make Evenity unsafe
• You need glucocorticoid-induced osteoporosis treatment
• You prefer once-yearly dosing and have adequate renal function (GFR above 35 mL/min)

Reclast Is Not Right For You If:

• Your GFR is below 35 mL/min
• You have had severe hypocalcemia or are significantly vitamin D deficient (correct first, then treat)
• You are pregnant or planning pregnancy in the near term

Two Clinician Perspectives Worth Knowing

"Romosozumab offers a window of anabolic activity that no bisphosphonate can replicate. For a woman in her early 60s with a crush fracture and a spine T-score of -3.2, starting with Evenity and consolidating with Reclast gives us the best shot at meaningful bone mass restoration in a three-to-four year window." This perspective reflects emerging clinical practice aligned with the AACE/ACE 2020 Osteoporosis Clinical Practice Guidelines [3].

The Menopause Society 2023 position statement on osteoporosis states that "for women at very high risk, sequential anabolic-then-antiresorptive therapy is preferred over antiresorptive monotherapy" [4]. This directly underpins the Evenity-then-Reclast sequence.

Monitoring: What to Track and When

For both drugs, baseline assessment should include a 25-hydroxyvitamin D level (aim for above 30 ng/mL), serum calcium, and a DEXA scan. Both drugs require vitamin D and calcium supplementation to be adequate before and during treatment.

For Reclast: renal function (serum creatinine and estimated GFR) before each annual infusion. Bone density reassessment by DEXA at one to two years to gauge response.

For Evenity: a cardiovascular risk assessment before the first dose. Serum calcium and phosphorus monitoring because hypocalcemia may occur. DEXA at 12 months (at the end of the Evenity course) to document BMD gain before transitioning.

Both drugs require dental evaluation before starting, given the shared but rare risk of ONJ. Invasive dental procedures should be completed before beginning therapy when possible.